A Multi-Omics Study of Vasospastic Angina

Identification of the Key Factors Increasing the Risk of Vasospastic Angina Based on Multi-omics.

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05282511

Acronym

KIVAM

Enrollment

1200

Registered

2022-03-16

Start date

2012-01-31

Completion date

2022-12-31

Last updated

2022-03-16

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Vasospastic Angina

Brief summary

This is a observational study to identify the key factor associated with vasospastic angina and to explore the prognosis of the participants. The study will recruit 400 patients with vasospastic angina, 400 healthy controls and 400 patients with acute myocardial infarction. Next generation sequencing, metabolome and proteomics will be performed in these participants.

Interventions

None listed

Study design

Observational model

COHORT

Time perspective

RETROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to No maximum

Healthy volunteers

Yes

Inclusion criteria

* 18 years of age or older * diagnosed as vasospastic angina

Exclusion criteria

* participate in any drug clinical trials within 3 months * patients with life-threatening complications, or the researchers determined that the survival time of patients with no more than 1 years * serious neurological disease (Alzheimer's disease, Parkinson syndrome, progressive lower limbs or deaf patients) * previous history of cancer or tumor, or pathological examination confirmed precancerous lesions (such as breast ductal carcinoma in situ, or atypical hyperplasia of the cervix)

Design outcomes

Primary

Measure	Time frame	Description
Cardiovascular Death	up to 48 months	Death from cardiovascular causes and any unknown death unless there was another certain cause
Stroke	up to 48 months	A rapid onset of a new focal loss of neurologic function caused by an ischemic central nervous system event with residual symptoms lasting at least 24 hours from their onset or leading to death
Myocardial Infarction	up to 48 months	The definition of myocardial infarction was consistent with the Third Universal Definition of Myocardial Infarction.

Secondary

Measure	Time frame	Description
Recurrent angina	up to 48 months	Recurrent angina
Rehospitalization due to cardiovascular causes	up to 48 months	Rehospitalization due to cardiovascular causes

Countries

China

Contacts

Primary ContactYang Sun, MD, PhD

sunyang.7@163.com

Backup ContactXin Xu, MD

mambaout8@163.com

Outcome results